Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:13 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction
NCT03037580 · United Therapeutics · PHASE3 · terminated · last registry update 2020-11-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Terminated by sponsor” | – | Registry record, United Therapeutics |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTGIR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-09-13Also stopped (terminated): Liquidia Technologies, Inc., Inhaled dry powder treprostinil (LIQ861) (NCT03884465)
- 2021-07-13Results posted on the registry: United Therapeutics, Inhaled Treprostinil + Placebo (NCT02630316)
- 2021-06-10Results posted on the registry: Stanford University, Oral treprostinil (NCT02663895)
- 2021-05-28Phase 3 first posted: United Therapeutics, Inhaled Treprostinil (NCT04905693)
- 2021-05-10Results posted on the registry: United Therapeutics, Oral Treprostinil (NCT01027949)
- 2021-02-23Results posted on the registry: Actelion, Selexipag + Placebo (NCT03078907)
- 2021-01-14Phase 3 first posted: United Therapeutics, Placebo + Inhaled Treprostinil (NCT04708782)
- 2020-12-31Phase 3 first posted: Liquidia Technologies, Inc., L606 inhalation suspension (NCT04691154)
- 2020-10-22Results posted on the registry: United Therapeutics, Oral treprostinil (NCT03043651)
- 2020-10-22Also stopped (terminated): United Therapeutics, Oral treprostinil (NCT03043651)
- 2020-10-06Phase 3 first posted: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA, Sotatercept + Placebo (NCT04576988)
- 2020-09-28Phase 3 first posted: Actelion, Selexipag (NCT04565990)
- 2020-09-11Results posted on the registry: Actelion, Macitentan + Tadalafil (NCT02558231)
- 2020-09-09Results posted on the registry: Rajan Saggar, Treprostinil (NCT00705133)
- 2020-09-07Results posted on the registry: Lung Biotechnology PBC, Esuberaprost + Placebo (NCT03657095)
- 2020-09-07Also stopped (terminated): Lung Biotechnology PBC, Esuberaprost + Placebo (NCT03657095)
- 2020-07-29Results posted on the registry: Children's Hospital Medical Center, Cincinnati, Treprostinil + Placebo (NCT02769624)
- 2020-07-29Also stopped (terminated): Children's Hospital Medical Center, Cincinnati, Treprostinil + Placebo (NCT02769624)
- 2020-07-14Results posted on the registry: United Therapeutics, APD811 + Placebo (NCT02279160)
- 2020-06-04Results posted on the registry: Eli Lilly and Company, Treprostinil + Placebo (NCT02770521)
- 2020-03-03Also stopped (withdrawn): Jewish General Hospital, HypotonicTreprostinil Solution + Eutonic Treprostinil Solution (NCT01615627)
- 2020-02-28Results posted on the registry: Lung Biotechnology PBC, Beraprost Sodium 314d Modified Release Tablets + Placebo (NCT01908699)
- 2020-02-13Results posted on the registry: United Therapeutics, Treprostinil Diolamine + Placebo (NCT01560624)
- 2019-12-23Also stopped (withdrawn): Heidelberg University, Inhaled Iloprost + Placebo (NCT02482402)
- 2019-11-25Phase 3 first posted: Actelion, Selexipag + Placebo (NCT04175600)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision